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Abstract
Background: Many nephrology observational studies use renal registries, which have well known limitations. The
Canadian Kidney Disease Cohort Study (CKDCS) is a large prospective observational study of patients commencing
hemodialysis in five Canadian centers. This study focuses on delineating potentially reversible determinants of
adverse outcomes that occur in patients receiving dialysis for end-stage renal disease (ESRD).
Methods/Design: The CKDCS collects information on risk factors and outcomes, and stores specimens (blood,
dialysate, hair and fingernails) at baseline and in long-term follow-up. Such specimens will permit measurements of
biochemical markers, proteomic and genetic parameters (proteins and DNA) not measured in routine care. To
avoid selection bias, all consenting incident hemodialysis patients at participating centers are enrolled, the large
sample size (target of 1500 patients), large number of exposures, and high event rates will permit the exploration
of multiple potential research questions.
Preliminary Results: Data on the baseline characteristics from the first 1074 subjects showed that the average age
of patients was 62 (range; 50-73) years. The leading cause of ESRD was diabetic nephropathy (41.9%), and the
majority of the patients were white (80.0%). Only 18.7% of the subjects received dialysis in a satellite unit, and over
80% lived within a 50 km radius of the nearest nephrologist’s practice.
Discussion: The prospective design, detailed clinical information, and stored biological specimens provide a wealth
of information with potential to greatly enhance our understanding of risk factors for adverse outcomes in dialysis
patients. The scientific value of the stored patient tissue will grow as new genetic and biochemical markers are
discovered in the future.
Background
More than 1 million patients with end-stage renal dis-
ease (ESRD) receive renal replacement therapy (RRT)
worldwide in the form of dialysis or transplantation, and
this number is projected to reach 2.2 million by the year
2030 [1-3]. In Canada, about 21,000 individuals require
hemodialysis (HD) treatment for ESRD, with an
expected annual growth of 7% [4]. Developed nations
spend about 2-6% of their total healthcare budget for
the provision of RRT to their ESRD population, which
usually represents only about 0.02-0.6% of their total
population [5,6]. In addition, mortality for ESRD
patients is 10 to 1000 times greater than in age matched
controls with normal kidney function, and ESRD is also
associated with very low quality of life [7-10]. The high
costs of care for RRT, adverse outcomes and the
increasing burden of ESRD make it a major global pub-
lic health issue. * Correspondence: mtonelli@ualberta.ca
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with ESRD has been one of the major advances in medi-
cine [8]. Nonetheless, the limitations of dialysis for treat-
ment of ESRD remain problematic. As the number of
patients treated grows, the costs, and morbidity and
mortality remains high despite technical and scientific
improvements [8,11,12]. Despite intensive investigation,
our knowledge of factors that mediate uremic complica-
tions among people treated with dialysis remains
inadequate [8,13].
Observational studies are important sources of infor-
mation to close knowledge gaps in every clinical disci-
pline. However, most observational studies in ESRD have
collected either good quality information on a small
number of individuals, or poorer quality data on a much
larger number of individuals. Many existing observational
data are derived from renal registries such as the United
States Renal Data Systems (USRDS) [5], European Renal
Association - European Dialysis and Transplant Associa-
tion (ERA-EDTA) [14], and Australia and New Zealand
Dialysis and Transplant (ANZDATA) [15]; or from pro-
spective studies such as the Dialysis Outcomes and Prac-
tice Pattern Study (DOPPS) [16], the choices for Healthy
Outcomes in Caring for ESRD (CHOICE) Study [17], and
European Uraemic Toxins (EUTox) Work Group data-
base [13]. Although these studies have made substantial
contributions to our knowledge about uremia and its
optimal treatment, they may have limitations including
suboptimal statistical power, lack of detail in data collec-
tion, or inability to store a comprehensive battery of bio-
logical specimens for future analyses.
The Canadian Kidney Disease Cohort Study (CKDCS)
is a large prospective observational study of patients
commencing dialysis in five Canadian centers serving
ethnically mixed populations (Vancouver, Calgary,
Edmonton, Ottawa, and Toronto). This novel study
focuses on identifying the potentially reversible determi-
nants of the major complications associated with dialysis
in an incident cohort of adult patients.
The key research objectives for the CKDCS are:
1. To assemble a prospective cohort of incident
Canadian hemodialysis patients and associated data-
base which contains research-quality information on
patient characteristics, comorbid diseases and rou-
tine and novel laboratory markers and genetic data.
2. To utilize data from the cohort to test specific
hypotheses about the independent relation between
biochemical and genetic markers and cardiovascular
disease (CVD) risk and outcomes such as mortality,
hospitalization and quality of life measures
3. To rapidly capture information on the characteris-
tics and health history of incident hemodialysis
patients, using a structured patient interview and
review of medical records.
4. To operate a specimen management and storage
system so that diverse specimens (blood, dialysate,
fingernails, hair) can be collected at dialysis initiation
and eventually be assayed by new biochemical and
genetic assays.
5. To make the data available to other academic
investigators and collaborators if required.
Methods
In order to have the most representative registry, the
CKDCS enrolls all incident adult (≥18 years of age)
hemodialysis patients from the five participating renal
programs. The sole exclusion criterion is failure to pro-
vide informed consent.
Recruitment
All subjects commencing chronic hemodialysis (HD) are
approached by study staff within 8 weeks of commen-
cing dialysis therapy. A variety of options for participat-
ing in the study are offered, depending on the interests
of the patient (Appendix 1).
Medical Data Collection
Consenting participants undergo a structured interview
to collect detailed data on demographic characteristics,
medical history, social history and satisfaction with
care. Information from the clinical record is used to
supplement the history. At the time of the first annual
follow-up visit, study subjects in Edmonton, Calgary
and Vancouver independently complete a Kidney Dis-
ease Quality of Life Questionnaire (KDQOL), Health
Utility Index questionnaire (HUI version 3) and an
Attitudes Toward Transplantation Questionnaire. To
avoid unnecessary expenditures on laboratory tests,
routine test results (complete blood count [CBC], urea,
creatinine, electrolytes, calcium, phosphate, parathyroid
hormone [PTH]) are captured in the study database
using either a direct data link or entered manually by
study personnel (Table 1).
Study visits are conducted at baseline, month 6, year
1, year 2, year 3, year 4, year 5 and then every 5 years
thereafter. The baseline study visit is conducted within
8 weeks of initiating chronic dialysis. Follow-up visits
are completed ± 2 month of the scheduled visit date
(Table 2).
Whenever necessary, a translator is present during the
consent and interview procedures. Quality of Life ques-
tionnaires (which must be completed by the study sub-
ject without assistance) are available in English, French,
Chinese and Spanish and may be completed by hand or
electronically.
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Blood, dialysate effluent, fingernail and hair samples
are obtained at baseline, 6 months, 12 months and at
each study visit thereafter, according to standard pro-
tocols. Blood samples are immediately divided into
multiple aliquots, from which plasma, DNA, RNA and/
or cells are extracted and separately stored. Dialysate
specimens are aliquoted to allow future measurement
of genetic and cellular material. Specimens are frozen
at -80 degree Celcius. Specimens are sent to the Cana-
dian Biosample Repository in Edmonton and are
labeled using a unique study identifier to maintain
confidentiality.
Source Water Collection
Source water used for dialysate is collected in triplicate
four times annually from each dialysate unit (including
satellite dialysis locations). Patients are also asked to
bring a sample of their drinking water from home on
two separate days during one week at baseline and
month 6. Source water specimens are shipped to the
study laboratory and frozen for future analysis.
Coronary CT and Cardiac MRI
A subset of 500 subjects will undergo imaging to deter-
mine the presence and extent of Coronary Artery Calci-
fication (CAC) and Cardiac geometry including Left
Ventricular Hypertrophy (LVH). CAC will be assessed
by multi-slice computed tomography at two points dur-
ing the study: baseline (within 3 months of dialysis
initiation) and 12 months after dialysis initiation. All
CT scans will be reported locally by an experienced
reader for the presence, distribution and amount of
CAC, using dedicated software (manufacturer depen-
dent). Calcium mass, plaque volume and Agatston score
will be calculated [18].
Table 1 Data Collection Synopsis
Category Data Collected Baseline Followup
Background and
demographic information
Age, sex, race, dialysis start date, education, employment status, postal code (to allow linkage
to census data), provincial health card number (for linkage), hospital unit number, social
support
X
Medical history Cause(s) of ESRD, tobacco use/dose, coronary disease, chronic heart failure, previous
arrhythmia, cerebrovascular disease, peripheral vascular disease, diabetes mellitus, pulmonary
disease, neurologic disease, psychiatric disease, musculoskeletal disease, gastrointestinal and
hepatic diseases, cancer, eye disease, hepatitis, HIV, family history of premature CAD in first
degree relatives
X
Pre-ESRD treatment Nephrologist visit, interval between first nephrology visit and ESRD, vascular access, relevant
labs (Hb, Ca, PO4, HCO3, albumin)
X
Vital signs BP, HR, weight, height X X
Dialysis prescription Time, dialyzer, dialysate composition, blood flow, Bioimpedance measurements X X
Functional Status Specific study questionnaire, Health Utilities Index X X
Laboratory data Routine laboratory data from dialysis monthly bloodwork X X
Frozen blood for biochemistry
Frozen plasma for special tests and proteomic studies (will not be thawed or refrozen)
Frozen blood for DNA/RNA
Frozen dialysate
Excess/deficiency of trace
elements
Source water collection from home and dialysis unit X X
Residual renal function Timed urine collection for urea/creatinine X X
Medications List of medications and dose X X
Vascular access history Type and location of current access, number of prior temporary and permanent accesses X X
Vascular access events Type, location at start and end of interval; all changes in access status; procedures, creation/
placement
XX
Hospitalizations Dates, diagnosis, and procedures for each interval hospitalization X
Interval status Dialysis status at end of reporting interval, date and cause of death X
Determinants of Transplant
referral
Patient and physician attitudes toward transplantation, intervals from transplant referral to
transplant activation.
XX
Quality of life Kidney Disease Quality of Life Instrument (KDQOL) X X
Satisfaction with care Specific study questionnaire X
Coronary artery calcification/
Cardiac geometry
Coronary CT scan/Cardiac MRI X
BP = Blood pressure, CAD = Coronary Artery Diseas, ESRD = Endstage renal disease, HR = Heart rate, KDOOL = Kidney Disease Quality of Life Instrument,
Hb = Haemoglobin, Ca = Calcium, PO4 = Phosphate, HCO3, = Bicarbonate.
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tion, all sites must: (1) use ≥64-slice multidetector Com-
puted Tomography Scan (MDCT) technology or better
(2) led by level 3 accredited cardiologist/radiologist.
Before the start of the study, each site will send ten anon-
ymized CAC reports and data sets to the core lab for
assessment of image quality/data transfer/reproducibility
of results. For sites demonstrating excessive variation, the
core lab will review the site protocol/analysis tools and
work with the site to reach the standard needed.
Cardiac geometry (including LVH) will be assessed by
cardiac magnetic resonance imaging (CMRI). Scanning is
performed at baseline and at 12 months after dialysis
initiation in these 500 participants. Left ventricular (LV)
mass, and change in LV mass are analyzed as both quan-
titative traits and dichotomous end-points. All CMRI
scans will be analyzed using dedicated software (manu-
facturer dependent) and reported locally by an experi-
enced reader. Absolute and normalized to body surface
area (BSA) left ventricular muscle mass, end diastolic
blood pool volume, end systolic blood pool volume, ejec-
tion fraction, cardiac output and stroke volume will be
calculated. Results forwarded to the core lab together
with image data. To ensure uniformity and high quality
image acquisition; all sites must: (1) use 1.5T CMR
sequences (2) led by a level 3 CMRI certified radiologist/
cardiologist. Before the start of the study, each site will
send ten anonymized LV function data sets and results to
the core lab for assessment of image quality/transfer cap-
ability and reproducibility of results. For sites demon-
strating excessive variation, the core lab will review the
site protocol/analysis tools and work with the site to
reach the standard needed. An additional two studies will
be requested to ensure the site fulfils all requirements.
Bacteremia Screening
All participating renal programs perform ongoing sur-
veillance of bacteremia in HD patients as an infection
control initiative. Renal programs routinely record the
date and microbiological species associated with positive
blood cultures, as well as patient-specific information
such as health card number and demographic data. Data
on the management of bacteremia are also collected
including: whether antibiotics were prescribed, antibiotic
type/duration, whether catheter removal/exchange
occurred and whether the event was resolved. Recurrent
bacteremia is defined as a repeat positive blood culture
with the same species within 6 months of the index
event, according to current guidelines [19]. Periods of
follow-up and any hospitalizations for infection or infec-
tious complications within 2-8 weeks of the index cul-
ture are recorded.
Death Adjudication
Study subjects who die are identified by monthly follow-
up by study coordinators; date of death is obtained from
the renal programs. A prospectively defined method is
used to ascertain the cause of death as previously pub-
lished [20,21]. A standardized form is completed by a
study coordinator after obtaining the date of death. The
forms are supplemented by information provided by the
patient’s physicians and next of kin where appropriate.
This form, together with copies of the medical record,
discharge summaries, autopsy/coroner’s report (if avail-
able) are obtained and sent to two investigators for
independent classification of the cause of death. On
occasions when the cause of death differs between adju-
dicators, the site investigator acts as the tie breaker.
Additional Data Sources
Whenever possible, other data sources are utilized by
linking patient identifiers for analysis of outcomes and
their determinants (Figure 1). All data linkages are done
to ensure the confidentiality of study subjects. Security
measures will include: the encryption of subject identi-
fiers and corresponding data, transfer of encrypted data
Table 2 Study Procedure Schedule
Procedures Study Visits Baseline Month 6 Month 12 Month 18 Year 2 and yearly
Consent X
Subject interview X X X X
Medical record review X X X X
Coronary CT (separate consent form) X
Sample collection (blood, dialysate/effluent, finger/toe nails, hair) X X X X
Home tap water collection X X
Genetic sample collection (separate consent form) X
Control genetic sample collection (separate consent) X
Bioimpedance measurement X X X X X
KDQOL X X X X
Attitudes toward Transplant X
CT = Computed tomography, KDOOL = Kidney Disease Quality of Life Instrument.
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or through secure FTP sites. The following data sources
may be utilized:
Local Renal Program Databases
Contain detailed information on pre-dialysis, dialysis and
kidney transplant patients. Data linkage will provide
information on medication use, laboratory results, bacter-
emia incidence and management, and access blood flows.
Provincial Health Authorities Databases
The use of administrative data sources permit determi-
nation of disease incidence and prevalence using vali-
dated algorithms for common medical conditions such
as hypertension [22], diabetes [23,24], acute myocardial
infarction [24], congestive heart failure [25] and stroke
[26], as well as assessment of clinical, health outcomes
and costing information [27]. In addition to routine
demographic information and dates of death, some
administrative databases include information to permit
the assessment of Aboriginal ethnicity, socio-economic
status, and a six-digit postal code which enables unique
geographic information system (GIS) analyses to be per-
formed [27]. Hospitalization information via diagnostic
and procedure codes using ICD-9-CM and ICD-10) is
available [27].
Canadian Census
Census data includes the population counts of each geo-
graphic area, as well as information, for example, on
whether it is in a rural location (Statistics Canada defini-
tion) [28], average income, education levels, etc. The
six-digit residential postal code for each subject is linked
to these data using the Postal Code Conversion file.
Provincial Laboratory Services
Computerized provincial databases are used to obtain
laboratory data recorded outside of the renal programs.
A. Clinical
1. Socio-demographic 
characteristics (medical history, 
social history and satisfaction 
with care information). 
Information from the clinical 
record is used to supplement the 
history.
2. Qualitative Data obtained via 
KDQOL and an Attitudes Toward 
Transplantation Questionnaire 
B. Laboratory  data
1. Blood –multiple aliquots for DNA, 
RNA, cells and plasma will be 
extracted and stored
2. Urine, and Dialysate/effluent: 
aliquots stored for future 
measurements of genetic and 
cellular material
3. Finger/toe nail
4. Source water collection- stored 
for future analysis
5. Bacteremia screening: data on 
episodes and treatment
C. Imaging
1. Coronary CT  for  vascular 
calcification
2. Coronary  MRI for cardiac 
geometry ( left ventricular mass & 
function)
D. Others
1. Death adjudication, comorbidities, 
ESRD causes codes, ECG, 
Smoking
A. Local Renal Program Databases
1. Additional laboratory data
2. Medications use; eg. iron, erythropoetin
use
3. Dialysis access utility data
4. Dialysis access  infections episodes and 
treatment data
5. Transplant assessment and status
B. Provincial Health Authorities 
databases
1. Physicians claims; data and location of 
service, Diagnostic code (ICD 9), 
Provider specialty, Cost.
2. Inpatient encounters; Admission and 
discharge dates, Diagnostic and 
procedure costs (ICD 9& 10, Costs, 
Case mix group
3. Ambulatory care; date, nature and 
location of service, Diagnostic and 
procedure costs, Costs, Case mix 
group
4. Medications usage; formulary drugs, 
prescription date , cost & quantity
5. Date of birth, gender, First nation status
D. Provincial Laboratory Services
1. Results from haematological, biochemical, 
serological and immunological tests
2. Others; tumour markers, genetics, etc
A. Cross-sectional
1. Role of anemia, bone 
metabolism, inflammatory marks, 
endothelial dysfunction, genetic 
factors, and socio-demographic 
factors (age, gender, race, first 
nation status, residence location, 
socio-economic status) on CVD 
at dialysis inception
2. Assessment of pre-dialysis care 
and its impact on adverse 
outcomes
3. Access and utility of kidney 
transplantation
B. Prospective
1. Determinants of all-cause 
mortality
2. Determinants of dialysis access 
failure and consequences
3. Determinants of poor quality of 
life and functional status
4. Assessment of care delivery 
quality, impact and satisfaction
5. Bacteremia screening: data on 
episodes and treatment
Additional Data Sources 
C. 2001 Canadian Census
1. Postal code – rural/urban residence
2. Socio-economic status-median household 
income
CKDCS Primary Data  Potential Data Use Applications 
Figure 1 Data sources utilized by linking patient identifiers for elaborate analysis of outcomes and their determinants from the
primary data collected in the study, and that obtained from additional sources (Abbreviations: CKDS = Canadian Kidney Disease
Cohort Study, CT = Computed tomography, CVD = Cardiovascular disease, ECG = Electrocardiogram, ESRD = Endstage Renal Disease,
MRI = Magnetic Resonance Imaging, KDQOL, Kidney Disease Quality of Life).
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Study data are stored in a Microsoft SQL database cre-
ated specifically for this project. Wherever possible, free
text fields, blank values and open-ended questions have
been eliminated from the database. “Not available” and
“not applicable” values are permitted. Data from
enrolled subjects are either entered directly into the
database using a Microsoft Access interface through
dedicated, password controlled laptop computers or are
first collected on paper forms. All paper forms identify
subjects exclusively by initials and study numbers. Qual-
i t ya s s u r a n c er e p o r t sa r eg e n erated on a monthly basis
for the purposes of ensuring standard and compliance
with the study protocol. Working copies of the database
used to perform analyses are stripped of uniquely identi-
fying information such as provincial health care number.
Ethics Approval
The institutional review boards at the participating cen-
ters approved the study, and it is conducted according
to the Helsinki declaration for medical research in
humans.
Planned Analyses
The sample size and large number of exposures together
with the high event rate will permit the exploration of
multiple potential research questions. In addition, the
availability of stored blood samples will allow the testing
of hypotheses raised by data which becomes available in
the future. The target sample size is 1500 subjects.
Potential Use of Study Data
This study will provide a combination of cross-sectional
and prospective clinical data and biological specimens of
huge potential for conduct of high quality observational
studies and clinical trials (Figure 1).
Potential Applications of the Cross-sectional data:
1. Investigating the role of anemia, bone metabolism,
inflammatory markers, endothelial dysfunction,
genetic factors, and socio-demographic factors
(age, gender, race, first nation status, residence location,
socio-economic status) on CVD at dialysis inception
2. Assessment of pre-dialysis care and its impact on
adverse outcomes
3. Access and utility of kidney transplantation
Potential Applications of the Prospective data:
1. Determinants of all-cause mortality
2. Determinants of dialysis access failure and
consequences
3. Determinants of poor quality of life and functional
status
4. Assessment of care delivery quality, impact and
satisfaction
5. Bacteremia screening: data on episodes and
treatment
6. Potential for biomarker discovery and validation
using array technology
Preliminary Results
Data on the baseline characteristics of the first 1074
subjects enrolled are presented in Table 3. The average
age of patients was 62 (range; 50-73) years. The leading
cause of ESRD was diabetic nephropathy. The majority
of patients enrolled to date were white. Overall 86.5%,
50.7%, 46.7%, 20.2% and 12.7% patients had a history of
hypertension, diabetes mellitus, coronary artery disease,
congestive heart failure and cerebrovascular disease
respectively. Only 15.7% of the study subjects were cur-
rent smokers. The predominant dialysis access in use
was tunneled central venous catheter (60.4% of the
cohort). The baseline laboratory parameters (median
[interquartile range]) were albumin: 34 (30-37) g/L, cal-
cium: 2.2 (2.0-2.3) mmol/L, phosphate: 1.6 (1.2-1.9)
mmol/L, PTH: 26.2 (10.7-45.8.3) pmol/L, hemoglobin:
99 (89-109) g/L, ferritin: 252 (136-472) ug/L, and trans-
ferrin saturation: 24 (17-31)%. The average Kt/V was 1.4
(1.2-1.7) %. Only 18.7% of the subjects received dialysis
in a satellite unit, and over 80% lived within 50 km of
the nearest nephrologist.
Discussion
The CKDCS uses a unique study design to assemble a
cohort of subjects recruited at hemodialysis inception in
Canada to prospectively collect detail clinical and
laboratory data as well as novel biochemical and genetic
markers. While clinical trials are considered best evi-
dence to guide clinical care and policy, this study will
inform important knowledge gaps for several reasons
[29]. First, observational studies are important sources
of hypothesis-generating data about chronic diseases
and their treatments [30]. Second, collecting good qual-
ity observational data may reduce the risk of incorrect
inferences [21,31], based on retrospective studies or less
detailed registry data [4,5,8,13,16]. Third, comprehensive
high quality observational studies of dialysis patients
remain an important research focus [21,31].
An ideal cohort study in ESRD should consist of a
well-characterized population of incident patients to
avoid prevalence-incidence bias [29,30,32]. The CKDCS
involves patients recruited at inception of dialysis with
meticulous data collation, and monitoring for outcomes.
The study will be large enough to allow adequate power
to explore covariates simultaneously, and have sufficient
variability in patient and treatment characteristics to
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characteristics and various outcomes under investiga-
tion. The study will collect and quantify known covari-
ates that might potentially affect relevant outcomes in
dialysis patients (death, hospitalizations, access failure,
quality of life, cost), and employ an accurate, unbiased
method of ascertaining such outcomes.
The additional strength and novelty of this study is
the collection and storage of materials (blood, dialysate,
fingernails, hair, etc) so that new risk factors such as the
impact of trace elements on outcomes can be measured
and studied in the future as they arise. The storage of
genomic DNA and plasma for future analyses is a
strength given the emerging importance of genetic and
proteomic analysis [33-35]. This has great potential for
Table 3 Preliminary data on baseline patients’
characteristics
Cohort patients, N(%)
N 1074
Age* 62 (50, 73)
Male 662 (62)
Race 1074
White 813 (76)
Aboriginal 81 (8)
East Asian 47 (4)
South Asian 42 (4)
Other 91 (8)
Marital status 937
Married 581 (62)
Single 163 (17)
Divorced 104 (11)
Widow 89 (9)
BMI, kg/m
2* 26 (22, 31)
Cause of ESRD 916
Diabetic nephropathy 380 (41.5)
Glomerulonephritis 154 (16.8)
Hypertensive/ischemic renal disease 68 (7.4)
Polycystic kidney disease 49 (5.3)
Other 265 (28.9)
Comorbidity
Arrhythmia 214 (20.9)
Cancer 156 (14.4)
Cerebrovascular disease 130 (12.7)
Congestive heart failure 202 (20.2)
Chronic lung disease 125 (12.7)
Claudication 131 (13.3)
Coronary disease 481 (46.7)
Dementia 28 (2.8)
Diabetes mellitus 515 (50.7)
Diabetic retinopathy 224 (23)
HBV 30 (2.9)
HCV 39 (3.8)
HIV 2 (.2)
Hypertension 785 (86.5)
Pericarditis 27 (2.7)
Peripheral neuropathy 239 (24.2)
Peripheral vascular disease 209 (20.6)
Prior cardiac arrest 20 (2)
Psychiatric illness 148 (15)
Seizure disorder 34 (3.4)
ECG 310 (28.7)
Normal 61 (5.6)
Abnormal 142 (13.1)
No result 107 (9.9)
ECHO 320 (29.6)
Normal 14 (1.3)
Abnormal 50 (4.6)
No result 256 (23.7)
Table 3 Preliminary data on baseline patients’
characteristics (Continued)
Current Smoker 154 (15.7)
CLINICAL MANAGEMENT
Satellite HD unit
€ 201 (18.7)
Type of access 510
AVF 138 (27.1)
PTFE 10 (2)
Non tunnel CVC 42 (8.2)
Tunnel CVC 308 (60.4)
LABORATORY MEASURES*
Albumin, g/L 34 (30, 37)
Calcium, mmol/L 2.2 (2, 2.3)
Calcium X phosphate, mmol
2/L
2 3.6 (2.9, 4.5)
Creatinine, μmol/L 534 (424, 682)
Ferritin, μg/L 252 (136, 472)
Hemoglobin, g/L 99 (89, 109)
Phosphate, mmol/L 1.6 (1.2, 1.9)
PTH, pmol/L 26.2 (10.7, 45.8)
Transaturation, % 24 (17, 31)
Urea, mmol/L 18.6 (14.6, 23.5)
Kt/V 1.4 (1.2, 1.7)
Distance to Nephrologist, km 482
≤50 387 (80.3)
51 - 100 43 (8.9)
101 - 200 30 (6.2)
> 200 33 (6.8)
*Median (interquartile range).
€all clinics outside of Edmonton, Calgary and Vancouver considered satellite
unit.
HD Hemodialysis; BMI body mass index; ESRD end-stage renal disease; HBV
Hepatitis B virus; HCV Hepatitis C virus; HIV Human immunodeficiency virus;
ECG electrocardiogram; ECHO echocardiogram; AVF Arterial Venous Fistula; PD
Peritoneal dialysis; PTFE Polytetrafluoroethylene; CVC Central venous catheters;
PTH parathyroid hormone.
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ogy in future.
These unique characteristics make this study novel,
topical and an extension of the existing observational
databases on ESRD population. The largest such database
is the USRDS, which although extremely useful, derives
much of its information from billings data, which has sig-
nificant limitations [5]. For example, medical profes-
sionals do not generally enter data themselves, and the
information collected is chiefly limited to the elements
required for Medicare reimbursement. In general, quanti-
fied risk factors and information on laboratory results
and medication use are not available. More recently, the
DOPPS has sought to remedy some of these aforemen-
tioned limitations, but has been limited by lack of a bio-
banking platform and prospective imaging studies [16].
In conclusion, the CKDCS will capitalize on the
unique demographic and multiethnic characteristics of
the Canadian dialysis population, a supportive Canadian
regulatory climate, and the established and productive
collaborations between Canadian nephrology investiga-
tors to address the limitations of existing databases. It
will also provide novel information on determinants of
adverse outcomes in hemodialysis patients, because of
its unique combination of detailed prospectively col-
lected information and the availability of stored biologi-
cal specimens. This will provide new platforms for
clinical and translational observational studies and clini-
cal trials among dialysis patients in the future.
Appendix 1: Study Consent Pathway
All subjects wishing to participate in the study are
required to sign the Main CKDCS consent form which
permits collection of health history and/or clinical
laboratory data at baseline and during follow-up and
will allow future analysis of stored blood specimens for
non-genetic laboratory assays to examine “factors that
influence the cause or treatment of heart or kidney
disease”.
1. Genetic Sample Consent - The Genetic Sample
Consent form will permit proteomic and genetic testing
(plasma and DNA) from stored peripheral blood and
other available biological samples such as tissue, to
examine the same research questions.
Both consent forms will explicitly state that:
￿ data and specimens may be obtained and used
after the death of the subject
￿ provincial and national databases can be accessed
to provide obtain other information about their
health
2. Control Genetic Sample consent - Whenever pos-
sible, control blood samples are collected from a family
member or acquaintances of the study subject. These
samples are used as controls for the genetic analyses.
Eligible family members or acquaintances will include
those who do not have kidney disease and are willing to
provide samples with the understanding that they are
used in an anonymous fashion as the control in genetic
analyses. The same safeguards are taken to protect the
privacy of these control subjects, as is taken for partici-
pants treated with dialysis.
3. CT consent - The Coronary CT consent permits a
multi-slice coronary CT scan at baseline.
List of Abbreviations used
ANZDATA: Australia and New Zealand Dialysis and Transplant; BSA: Body
Surface Area; CAC: Coronary Artery Calcification; CHOICE: Choices for Healthy
Outcomes in Caring for ESRD; CKDCS: Canadian Kidney Disease Cohort
Study; CMRI: Cardiac Magnetic Resonance Imaging; CBC: Complete blood
count; CT: Computed tomography; CVD: cardiovascular disease; DOPPS:
Dialysis Outcomes and Practice Pattern Study; ERA-EDTA: European Dialysis
and Transplant Association; ESRD: End-stage renal disease; EUTox: European
Uraemic Toxins; GIS: Geographic Information System; HD: hemodialysis; HUI:
Health Utility Index questionnaire; KDQOL: Kidney Disease Quality of Life
Questionnaire; LVH: Left Ventricular Hypertrophy; MDCT: multidetector
Computed Tomography Scan; PTH: Parathyroid hormone; RRT: Renal
Replacement Therapy; USRDS: United States Renal Data Systems.
Acknowledgements and Funding
The CKDCS is being funded by the Canadian Institutes of Health Research
(CIHR), Abbott Laboratories, Alberta Heritage Foundation for Medical
Research, and the Northern Alberta Renal Program.
Author details
1Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
2Department of Medicine, Massachusetts General Hospital, Boston, USA.
3Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
4Division of Nephrology, University of British Columbia, Vancouver, BC,
Canada.
5Division of Nephrology, University Health Network, University of
Toronto, Toronto, Ontario, Canada.
6Department of Medicine, University of
Ottawa, Ottawa, Ontario, Canada.
7Department of Pathology & Laboratory
Medicine, University of British Columbia, Vancouver, BC, Canada.
8Department of Laboratory Medicine & Pathology, University of Alberta,
Edmonton, Alberta, Canada.
Authors’ contributions
All authors have made substantial contributions to the development of the
manuscript, and have all been involved in revising it for important
intellectual content and approved the final version.
Competing interests
The authors declare that they have no competing interests.
Received: 11 January 2011 Accepted: 16 February 2011
Published: 16 February 2011
References
1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME,
Jaber BL, Jadoul M, Levin A, et al: Chronic kidney disease as a global
public health problem: approaches and initiatives - a position statement
from Kidney Disease Improving Global Outcomes. Kidney Int 2007,
72(3):247-259.
2. Meguid El Nahas A, Bello AK: Chronic kidney disease: the global
challenge. Lancet 2005, 365(9456):331-340.
3. Snyder JJ, Collins AJ: KDOQI hypertension, dyslipidemia, and diabetes
care guidelines and current care patterns in the United States CKD
population: National Health and Nutrition Examination Survey 1999-
2004. Am J Nephrol 2009, 30(1):44-54.
Bello et al. BMC Nephrology 2011, 12:10
http://www.biomedcentral.com/1471-2369/12/10
Page 8 of 94. Anonymous: Treatment of End-Stage Organ Failure in Canada, 1999 to 2008.
Canadian Organ Replacement Register (CORR) 2010 [https://secure.cihi.ca/
estore/productFamily.htm?pf=PFC1403&locale=en&lang=EN&mediatype=0],
(Accessed 2nd November, 2010).
5. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B,
Liu J, Mau LW, McBean M, et al: United States Renal Data System 2008
Annual Data Report. Am J Kidney Dis 2009, 53(1 Suppl):S1-374.
6. De Vecchi AF, Dratwa M, Wiedemann ME: Healthcare systems and end-
stage renal disease (ESRD) therapies–an international review: costs and
reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999,
14(Suppl 6):31-41.
7. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL,
Akizawa T, Bommer J, Canaud BJ, Port FK, Held PJ: Health-related quality
of life among dialysis patients on three continents: the Dialysis
Outcomes and Practice Patterns Study. Kidney Int 2003, 64(5):1903-1910.
8. Himmelfarb JIT: Haemodialysis. N Engl J Med 2010, 363:1833-1845.
9. Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C: Quality of
life in patients treated with hemodialysis or peritoneal dialysis: what are
the important determinants? Clin Nephrol 2003, 60(5):341-351.
10. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA: The quality of life
and cost utility of home nocturnal and conventional in-center
hemodialysis. Kidney Int 2003, 64(3):1004-1011.
11. Weinhandl ED, Foley RN, Gilbertson DT, Arneson TJ, Snyder JJ, Collins AJ:
Propensity-matched mortality comparison of incident hemodialysis and
peritoneal dialysis patients. J Am Soc Nephrol 2010, 21(3):499-506.
12. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L,
Bragg-Gresham JL, Feldman HI, Goodkin DA, et al: Mortality and
hospitalization in haemodialysis patients in five European countries:
results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Nephrol Dial Transplant 2004, 19(1):108-120.
13. Anonymous: European Uraemic Toxins (EUTox) Work Group. 2010 [http://
uremic-toxins.org/imprint.html].
14. Ronco P: Disease classification: a pitfall of the ERA/EDTA registry? Nephrol
Dial Transplant 2010, 25(4):1022-1024.
15. Australia and New Zealand Dialysis and Transplant Registry. 2009
[http://www.anzdata.org.au/v1/working_group_members.html], (Accessed
16th November, 2010).
16. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The
Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data
elements, and methodology. Am J Kidney Dis 2004, 44(5 Suppl 2):7-15.
17. Sozio SM, Armstrong PA, Coresh J, Jaar BG, Fink NE, Plantinga LC, Powe NR,
Parekh RS: Cerebrovascular disease incidence, characteristics, and
outcomes in patients initiating dialysis: the choices for healthy
outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009,
54(3):468-477.
18. van der Bijl N, Joemai RM, Geleijns J, Bax JJ, Schuijf JD, de Roos A, Kroft LJ:
Assessment of Agatston coronary artery calcium score using contrast-
enhanced CT coronary angiography. AJR Am J Roentgenol 2010,
195(6):1299-1305.
19. Mermel LA: Prevention of intravascular catheter infections–insights and
prospects for hemodialysis catheters. Nephrologie 2001, 22(8):449-451.
20. Rocco MV, Yan G, Gassman J, Lewis JB, Ornt D, Weiss B, Levey AS:
Comparison of causes of death using HEMO Study and HCFA end-stage
renal disease death notification classification systems. The National
Institutes of Health-funded Hemodialysis. Health Care Financing
Administration. Am J Kidney Dis 2002, 39(1):146-153.
21. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M,
Bailey J, Delmez JA, Depner TA, et al: Effect of dialysis dose and
membrane flux in maintenance hemodialysis. N Engl J Med 2002,
347(25):2010-2019.
22. Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, Hill MD,
Ghali WA, McAlister FA: Validation of a case definition to define
hypertension using administrative data. Hypertension 2009,
54(6):1423-1428.
23. Hux JE, Ivis F, Flintoft V, Bica A: Diabetes in Ontario: determination of
prevalence and incidence using a validated administrative data
algorithm. Diabetes Care 2002, 25(3):512-516.
24. Austin PC, Daly PA, Tu JV: A multicenter study of the coding accuracy of
hospital discharge administrative data for patients admitted to cardiac
care units in Ontario. Am Heart J 2002, 144(2):290-296.
25. Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV:
Comparison of coding of heart failure and comorbidities in
administrative and clinical data for use in outcomes research. Med Care
2005, 43(2):182-188.
26. Kokotailo RA, Hill MD: Coding of stroke and stroke risk factors using
international classification of diseases, revisions 9 and 10. Stroke 2005,
36(8):1776-1781.
27. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P,
Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, et al: Overview of the
Alberta Kidney Disease Network. BMC Nephrol 2009, 10:30.
28. Heng D, Pong RW, Pitblado JR, Lagace C, Desmeules M: Sources of data
for rural health research: development of an inventory of Canadian
databases. J Agric Saf Health 2005, 11(2):219-227.
29. Stel VS, Jager KJ, Zoccali C, Wanner C, Dekker FW: The randomized clinical
trial: an unbeatable standard in clinical research? Kidney Int 2007,
72(5):539-542.
30. Jager KJ, Stel VS, Wanner C, Zoccali C, Dekker FW: The valuable
contribution of observational studies to nephrology. Kidney Int 2007,
72(6):671-675.
31. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J,
Mujais S: Effects of increased peritoneal clearances on mortality rates in
peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.
J Am Soc Nephrol 2002, 13(5):1307-1320.
32. Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C: Bias in clinical
research. Kidney Int 2008, 73(2):148-153.
33. Hong KW, Oh B: Overview of personalized medicine in the disease
genomic era. BMB Rep 2010, 43(10):643-648.
34. Ding L, Wendl MC, Koboldt DC, Mardis ER: Analysis of next-generation
genomic data in cancer: accomplishments and challenges. Hum Mol
Genet 2010, 19(R2):R188-196.
35. Borovecki F, Habek M: Development of novel genomic blood biomarkers
for neurodegenerative diseases. CNS Neurol Disord Drug Targets 2010,
9(6):669-678.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2369/12/10/prepub
doi:10.1186/1471-2369-12-10
Cite this article as: Bello et al.: Design and implementation of the
canadian kidney disease cohort study (CKDCS): A prospective
observational study of incident hemodialysis patients. BMC Nephrology
2011 12:10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bello et al. BMC Nephrology 2011, 12:10
http://www.biomedcentral.com/1471-2369/12/10
Page 9 of 9